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Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the
metabolic syndrome, whose criteria are risk factors for atherosclerotic cardiovascular disease. We
aimed to evaluate the prevalence of NAFLD, its association with subclinical atherosclerosis, and
factors that may account for this association in Mexican Americans. In a population based crosssectional sample drawn from the Cameron County Hispanic Cohort in Texas, carotid intima media
thickness (cIMT), an indicator of subclinical atherosclerosis, was measured. Abnormal carotid
ultrasound study was defined as mean cIMT >75th percentile for age and gender and/or plaque
presence. NAFLD was defined as steatosis by ultrasound in absence of other causes of liver
disease. Multivariable weighted regression analyses were performed to evaluate associations
between NAFLD and cIMT. Mean age was 50.4±1.2 years with 58.3% females. Mean body mass
index (BMI) was 31.0 ± 0.4 kg/m2, and 54.0% had the metabolic syndrome. NAFLD was highly
prevalent (48.80%); subjects with NAFLD had greater BMI, central obesity, fasting glucose levels,
and dyslipidemia, and were more likely to have the metabolic syndrome. Nearly one third of
subjects with NAFLD also had evidence of subclinical atherosclerosis (31.2%). After adjusting for
covariates, there was an independent association between NAFLD and increased cIMT only in
younger subjects <45 years (p=0.0328). Subjects with both abnormal liver and carotid ultrasound
studies tended to be obese, diabetic, and have the metabolic syndrome. In conclusion, NAFLD is
highly prevalent in this Mexican American cohort, with an independent association between
NAFLD and subclinical atherosclerosis among younger subjects; clustering of diabetes, obesity,
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and metabolic syndrome in this health disparity cohort increases the risk of both liver disease and
early atherosclerosis in young adults.
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Non-alcoholic fatty liver disease (NAFLD), a comprehensive term used to describe a
spectrum of metabolic fatty liver diseases, is the most common cause of chronic liver disease
in the United States.1 NAFLD is considered to be the hepatic manifestation of the metabolic
syndrome, whose criteria of central (truncal) obesity, hypertriglyceridemia, hypertension,
decreased high-density lipoprotein cholesterol, and insulin resistance are also important risk
factors for the development of atherosclerotic heart disease.2–3 Indeed, cardiovascular
disease accounts for 25% of deaths in patients with NAFLD versus 13% of deaths in patients
with other liver diseases.4 Although some investigations have shown a relationship between
NAFLD and coronary artery disease independent of other metabolic risk factors,5 other
studies have shown inconsistent results6–7 with relatively little known about the association
in minority groups.8 Hispanics and Latinos face a disparately increased prevalence of
coronary risk factors,9 and in particular, the metabolic syndrome has been shown to be
higher in Hispanics than in non-Hispanics.10 Similarly, NAFLD afflicts Mexican Americans
much more than non-Hispanic Whites and non-Hispanic Blacks (25% vs. 18% and 15%,
respectively).11–12 This study aimed to evaluate the prevalence of NAFLD, its association
with subclinical atherosclerosis, and the factors that may account for this association in
Mexican Americans.
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METHODS
The Institutional Review Board of the University of Texas Health Science Center at Houston
approved this study with all participants giving written informed consent. Study subjects
were drawn from the Cameron County Hispanic Cohort (CCHC), recruited from randomly
selected blocks according to the 2000 Census as described previously.13 The CCHC is a
homogenous community-dwelling Mexican American cohort living in Brownsville, Texas,
located on the lower Rio Grande River at the United States-Mexico border. Participants for
this study (n=407) were a subset of individuals drawn from the CCHC, on whom we had
obtained both a carotid ultrasound to assess carotid intima media thickness (cIMT) and liver
ultrasound to evaluate for fatty liver.
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Bilingual research nurses and field workers obtained demographics of the participants
including an extensive medical history as described in previous studies.13–14 Participants
with a documented history of prior heart attack or stroke were excluded from the study.
Anthropometric measurements were obtained including height, weight, and waist
circumference. The presence of hypertension was diagnosed using both questionnaires and
obtained sphygmomanometer measurements. The subject was deemed to have hypertension
if the patient self-reported a prior diagnosis of hypertension, was currently taking antihypertensive medications, or if his/her mean systolic blood pressure was ≥130 millimeters of
mercury (mm Hg) or the mean diastolic blood pressure was ≥85 mm Hg. Participants were
Am J Cardiol. Author manuscript; available in PMC 2018 September 11.
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asked to fast for at least 10 hours overnight before a visit to the Clinical Research Unit.
Laboratory studies performed included electrolytes, fasting lipid panel, hepatitis B and C
status, complete blood count, glycated hemoglobin, fasting plasma glucose, and adipokines.
High-sensitivity C-reactive protein levels were measured using a high-sensitivity
immunoassay (Dimension Vista 1500; Siemens Corporation, Washington, DC). Highsensitivity C-reactive protein levels >10 milligrams/liter were excluded from analysis as
such high levels likely represent acute illness.15 Metabolic syndrome was defined as the
presence of at least 3 of the following risk factors: 1) elevated waist circumference (≥102
centimeters in males and ≥88 centimeters in females), 2) elevated triglyceride (≥150
milligrams/deciliter) or treatment with triglyceride lowering medication, 3) low high density
lipoprotein cholesterol (<40 milligrams/deciliter in males and <50 milligrams/deciliter in
females) or treatment with high-density lipoprotein cholesterol raising medication, 4)
elevated blood pressure (systolic ≥130 mmHg and/or diastolic ≥85 mmHg) or treatment with
an anti-hypertensive medication, and 5) elevated fasting glucose (≥100 milligrams/deciliter)
or treatment with glucose lowering medication.16 Classification of diabetes was also both
self-reported and based on measurement of hemoglobin A1C (hemoglobin A1C >6.5) as per
the latest guidelines from the American Diabetes Association.17 Physical activity was
assessed using the International Physical Activity Questionnaire short-form (IPAQ);18
reported minutes of physical activity per week were weighted by a metabolic equivalent
(MET; multiples of resting energy expenditure) resulting in a physical activity estimate
expressed as MET-minutes per week.18
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Any individual who tested positive for hepatitis C antibody, hepatitis B surface antigen,
females with a self-reported history of ≥20 grams of alcohol per day, and males with a selfreported history of ≥30 grams of alcohol per day were excluded from this study. Liver
ultrasound was performed using an established protocol.19 Study participants were asked to
fast for at least 8 hours prior to the ultrasound examination. During the scan, liver
parenchyma was examined both subcostally and intercostally in the supine position as well
as in modified slightly oblique positions with the right arm above the head and the right leg
stretched during all respiration cycles to identify the best approach and to avoid artifacts
caused by the thorax. For a diagnosis of hepatic steatosis, the following features were
recorded: (1) ultrasonographic contrast between the liver and right kidney parenchyma; (2)
brightness of the liver; (3) deep attenuation of ultrasound penetration into the deep portion of
the liver and impaired visualization of the diaphragm; and (4) impaired visualization of the
borders of intrahepatic vessels and narrowing of their lumen. Trained technicians perform
ultrasonography with a 5 mega-Hertz transducer (Ch5-2, Siemens, Mountain View, CA).
The overall gain, initial gain, and time gain compensation settings were kept within a narrow
range. The ultrasonographic images were read and interpreted by a single blinded expert
reader.
Carotid ultrasound to evaluate subclinical atherosclerosis was performed with the Siemens
Acuson X300 ultrasound system (Malvern, PA) using a VF 13-5 linear array transducer as
described in previous studies.14 The protocol was designed following guidelines from the
American Society of Echocardiography consensus statement on subclinical vascular disease.
20 Both left and right common carotid arteries were imaged from 3 different angles for a
total of 6 images: anterior, lateral, and posterior images for both common carotid arteries.
Am J Cardiol. Author manuscript; available in PMC 2018 September 11.
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Carotid plaque presence was determined by examining the carotid bulb, its bifurcation and
the carotid branch arteries in addition to the common carotid artery. Carotid IMT was
measured using the Carotid Analyzer software (Medical Imaging Applications, Coralville,
IA), a semi-automated border detection program. Measurements were made at the R-wave of
the electrocardiogram on a minimum of 2 clips from each side and the results were
averaged. Mean cIMT was categorized as being either < or ≥75th percentile for age and
gender.20 Carotid plaque was defined as an area of wall thickening that was >50% of the
thickness of the surrounding wall. A single blinded expert reader similarly performed all
measurements. Replicate readings were performed on 5% of the cohort and the intra-class
correlation coefficient for our laboratory was 0.96. Abnormal carotid ultrasound study was
defined as mean cIMT thickness ≥75th percentile for age and gender and/or the presence of
carotid plaque.
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All descriptive results and the models reported were adjusted for the probability of sampling
using age and gender adjusted sampling weights and taking into consideration clustering
effects arising from multiple participants from the same household as well as census tracks
and blocks.13 Descriptive statistics of baseline demographics and clinical characteristics
were reported and compared by NAFLD/Abnormal Carotid Ultrasound groups. Data were
summarized as mean and standard error for continuous variables and frequency and
weighted column percentages for categorical variables. Continuous variables were compared
using survey-weighted linear regression models from which Tukey-Kramer-adjusted p
values were calculated. Survey-weighted logistic regression was used to compare categorical
variables and to obtain the Rao-Scott F-adjusted chi-square p values. Survey-weighted
multivariable linear regression model was constructed to evaluate the effect of abnormal
fatty liver ultrasound on cIMT adjusting for demographic and clinical variables found to be
significantly associated with cIMT with p-value<0.05. To determine factors associated with
both abnormal liver and abnormal carotid, we conducted survey-weighted multinomial
multivariable logistic regression. Potential multi-collinearity and interaction effects across
the predictors in the multivariable models were assessed. All analyses were performed using
SAS 9.3 (SAS, 2000). Statistical significance was set at p < 0.05.
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RESULTS
Demographic and biochemical characteristics are listed in Table 1. This study included 407
individuals with an average age of 50.4 ± 1.2 years and females making up 58.3% of the
sample. There was a high prevalence of coronary risk factors in this cohort. The majority of
the individuals were either overweight or obese (85.6%), and only 14.4% had a normal body
mass index (BMI) [mean BMI of 31.0 ± 0.4 kg/m2].
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NAFLD was demonstrated in nearly half (49.2%) of the study participants with no gender
difference in prevalence (42.2% in males and 57.8% in females, p=0.8800). Compared to
subjects without NAFLD, subjects with NAFLD had higher BMI (32.5±0.5 kg/m2 versus
29.5±0.7 kg/m2; p=0.0005), larger waist circumference (106.5±1.2 centimeter. versus
100.2±1.6 centimeter; p=0.0024), had higher fasting blood glucose (114.9±5.3 milligram/
deciliter versus 99.8±1.6 milligram/deciliter; p=0.0058) and hemoglobin A1C (6.4%±0.2
versus 5.8%±0.1; p=0.0006), had higher fasting triglycerides (168.6±7.6 milligram/deciliter

Am J Cardiol. Author manuscript; available in PMC 2018 September 11.

Gill et al.

Page 5

Author Manuscript

versus 127.0±6.4 milligram/deciliter; p<0.0001), had higher Homeostasis Model
Assessment Insulin Resistance Index (4.7±0.6 versus 3.1±0.3, p=0.0225), had lower high
density lipoprotein cholesterol levels (43.0±1.1 milligram/deciliter versus 47.8±1.6
milligram/deciliter; p=0.0107), and lower adiponectin levels (14.6±1.3 micrograms versus
20.8±1.4 micrograms; p=0.0017). Patients with NAFLD had higher prevalence of metabolic
syndrome compared to those without (70.1% versus 38.5%; p<0.0001). Age, gender, family
history, blood pressure, low-density lipoprotein cholesterol, level of physical activity, highsensitivity C-reactive protein, and other inflammatory markers did not differ significantly
between the two groups.
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The mean cIMT for the cohort was 0.7 ± 0.0 millimeter, with no gender differences
(p=0.4966). There was no difference in mean cIMT between those with NAFLD vs. those
without NAFLD (p=0.2679). More than one third of the cohort (35.1%) had abnormal
carotid ultrasound findings. Among those with NAFLD, 30.4% had evidence of subclinical
atherosclerosis. When participants were categorized into four groups based on normal or
abnormal carotid and liver ultrasound studies (Table 1 and Figure 1), there was a graded
increase in prevalence for metabolic syndrome (p<0.0001), obesity (p<0.0001), and diabetes
mellitus (p<0.0001) among groups.
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Using a multivariable survey weighted logistic regression model, the odds of the presence of
both abnormal carotid and liver ultrasound vs. normal carotid and liver ultrasound increased
by 5% with each 1 milligram/deciliter increase in fasting plasma glucose (odds ratio=1.05,
95% confidence interval 1.02–1.08), after controlling for age, gender, family history, BMI,
systolic blood pressure, fasting triglycerides, physical activity, and smoking status. In further
analysis, after controlling for covariates, using multivariable survey weighted linear
regression models in age domains, NAFLD was independently associated with mean cIMT
in younger individuals of ages < 45 years (p=0.0309), but not in older individuals of ages ≥
45 years (p=0.1891).

DISCUSSION
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This study shows for the first time that in young Mexican Americans (< 45 years of age), the
presence of NAFLD portends an increased risk of subclinical atherosclerosis independent of
traditional coronary risk factors. Although the independent association between NAFLD and
subclinical atherosclerosis has been demonstrated in young individuals by other
investigators,21–22 these studies involved non-Hispanic Whites and Blacks. To our
knowledge, this study is the first demonstration of this phenomenon in Hispanics. With a
national prevalence of approximately 20%, NAFLD is becoming a public health concern
with rising diabetes and obesity rates yearly especially in younger individuals. Indeed, in our
cohort, NAFLD was seen in nearly half of the sample (49.2%), which is more than twice the
prevalence reported nationally. Our study highlights the importance of screening for
subclinical atherosclerosis in individuals with NAFLD especially in those persons < 45 years
of age. The presence of NAFLD should alert the clinician to screen for early atherosclerosis,
with the goal of intensification of risk factor modification to reduce the risk of a first
cardiovascular disease event.

Am J Cardiol. Author manuscript; available in PMC 2018 September 11.
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We, along with others, have demonstrated very high prevalence of cardiovascular risk factors
among Hispanics,9,14,23 with Mexican Americans showing epidemic proportions for obesity,
diabetes, and the metabolic syndrome.14 The high prevalence of NAFLD in this minority
group is therefore not surprising, and our present study is consistent with previous reports
that showed that individuals with NAFLD were more likely to be obese, diabetic,
dyslipidemic, and have increased visceral adiposity. In this study, we also demonstrated that,
among Mexican Americans, adiponectin levels were lower in those with NAFLD compared
to those without NAFLD. This finding has also been found amongst Asians and nonHispanic Whites24–25 but to our knowledge is the first time to be reported among Mexican
Americans. Hypoadiponectinemia is hypothesized to be part of a general metabolic
disturbance characterized by ectopic fat accumulation in the central compartment and
dysfunctional adipose tissue.25 Our finding of reduced adiponectin levels in Mexican
Americans with NAFLD is consistent with these findings and supports the role of
adipocytokines in metabolism and glucose tolerance.
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Impaired fasting glucose is a major component of the metabolic syndrome. In this study,
among the cardiometabolic risk factors evaluated, only fasting plasma glucose remained an
independent risk factor for both NAFLD and subclinical atherosclerosis, after adjusting for
covariates in this cohort. For every 1 milligram/deciliter increase in fasting plasma glucose,
there was an increase in the odds of having both NAFLD and subclinical atherosclerosis by
5%. This is another novel finding, and is particularly relevant among Hispanics who have a
very high prevalence of diabetes and prediabetes. In this study, the association between
fasting plasma glucose and both NAFLD and subclinical atherosclerosis was independent of
BMI, waist circumference, or physical activity, suggesting that these factors do not modify
the risk for having both conditions. On the other hand, fasting plasma glucose appears to be
an important determinant for increased risk of both hepatic and vascular end organ damage
in this cohort. This is an intriguing finding, as it seems to emphasize the importance of
glucose control among diabetics and plasma glucose level maintenance in those who are not,
thereby posing potential therapeutic targets for prevention of these diseases in Mexican
Americans.
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A few limitations must be noted. This was a cross-sectional study and as such no causal
relationships can be made, however longitudinal follow-up studies are currently underway.
Although liver biopsy and magnetic resonance spectroscopy are considered the gold
standards for the diagnosis of NAFLD,26 these are invasive and/or expensive tests, which are
not feasible in this community dwelling cohort. Since individuals found to have NAFLD by
ultrasonography had to be at least in the moderate stage of the disease and this technique can
miss mild cases, the findings in this study represent probably more advanced disease states
thus increasing specificity of the diagnosis. In this study, we did not perform imaging studies
to quantitate visceral adiposity and more sensitive measures of central adiposity may yield
different results; these studies are underway.
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Weighted Prevalence of Metabolic Syndrome, Obesity and Diabetes among Mexican
Americans within Non-Alcoholic Fatty Liver Disease/Subclinical Atherosclerosis Groups.
(NAFLD = Non-Alcoholic Fatty Liver Disease)
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19.8±1.5

18.1±1.1
3.9±0.3
6.1±0.1
0.7±0.0
$36,547±$3,632
10.5±0.3
834.8±175.6

Adiponectin (mcg/mL)

Homeostasis Model Assessment Insulin Resistance
Index

Hemoglobin A1C, %

Mean Carotid Intima Media Thickness (mm)

Annual Household Income ($)

Education Amount (years)

Total MET-minutes of moderate and vigorous activity
per week

273 (58.3%)
108 (29.1%)
223 (54.0%)

Female
Smoker

Metabolic Syndrome

Categorical Variable Weighted Frequency

3.6±0.6

3.2±0.3

High Sensitivity C-Reactive Protein <10 (mg/L)1

46.6±1.2

43 (32.0%)

25 (18.9%)

89 (63.7%)

1288.4±466.2

10.5±0.5

$38,252±$6,630

0.6±0.0

5.6±0.1

2.9±0.3

105.4±3.8

45.5±1.0

124.9±9.1

107.7±2.0

147.4±5.2

Triglycerides (mg/dL)

176.7±3.9

Low Density Lipoprotein (mg/dL)

182.7±2.4

Total Cholesterol (mg/dL)

95.2±1.2

72.1±0.8

115.3±1.5

99.6±2.4

29.8±0.9

44.7±1.7

High Density Lipoprotein (mg/dL)

73.9±0.6

120.9±1.2

Systolic Blood Pressure (mm Hg)

107.2±2.9

103.3±1.0

Waist Circumference (cm)

Fasting Blood Glucose (mg/dL)

31.0±0.4

Body Mass Index (kg/m2)

Diastolic Blood Pressure (mm Hg)

50.4±1.2

n=129

n=407

Age (years)

Continuous Variable, mean ± SEM

Normal Carotid Study

Total Cohort

39 (48.6%)

25 (50.3%)

44 (51.5%)

844.7±297.7

10.6±0.8

$40,308±$7,932

0.8±0.0

6.1±0.1

3.4±0.6

22.0±2.6

2.7±0.5

105.6±5.4

49.8±3.5

130.2±8.9

182.2±6.4

106.8±3.3

73.0±1.7

126.7±2.6

101.2±2.1

29.1±0.9

60.8±2.2

n=70

Abnormal Carotid Study

Normal Liver

91 (64.4%)

38 (26.4%)

92 (63.4%)

672.5±215.0

10.5±0.5

$30,321±$4,183

0.6±0.0

6.0±0.1

3.8±0.3

15.0±1.5

3.2±0.5

108.4±3.2

43.0±1.2

160.5±9.3

183.6±3.7

104.9±2.9

75.4±1.0

120.8±1.8

105.5±1.2

32.5±0.4

48.1±1.4

n=148

Normal Carotid Study

50 (85.0%)

20 (30.5%)

50 (85.1%)

196.9±87.8

10.3±0.9

$42,322±$9,108

0.8±0.0

7.0±0.4

6.6±1.6

13.8±1.6

3.7±0.8

113.8±5.7

43.3±2.1

186.9±13.3

193.6±7.1

137.7±15.4

75.4±1.5

124.9±3.6

108.8±2.2

32.6±1.4

53.4±2.5

n=60

Abnormal Carotid Study

Presence of NAFLD

Cohort Demographics and Metabolic Characteristics. *Student’s t-test for continuous variables and Chi-square test for categorical variables.
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Table 1

<0.0001

0.0070

0.4147

0.0152

0.9925

0.3692

<0.0001

<0.0001

0.0445

0.0109

0.6029

0.6154

0.0641

0.0002

0.1692

<0.0001

0.0421

0.0005

0.0141

0.0018

<0.0001

p-value
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171 (43.3%)
50 (13.0%)
120 (29.5%)
151 (36.6%)
233 (54.7%)
89 (23.6%)
95 (20.9%)
52 (45.5%)
94 (28.5%)

Hypertension3

Family history of stroke or heart attack

Total Cholesterol ≥200 mg/dL

Triglycerides ≥ 150 mg/dL

High Density Lipoprotein <40 mg mg/dL in Males and
<50 mg/dL in Females

Low Density Lipoprotein ≥ 130 mg/dL

Diabetes Mellitus4

High Sensitivity C-Reactive Protein >3.0 mg/dL1

Met minimum recommendations for physical activity of
≥ 600 MET-minutes/week

42 (38.3%)

16 (47.9%)

10 (6.4%)

26 (23.1%)

65 (50.4%)

35 (26.5%)

31 (25.3%)

13 (6.7%)

39 (29.6%)

43 (32.1%)

12 (27.6%)

9 (38.2%)

20 (18.4%)

18 (29.9%)

30 (36.5%)

22 (21.3%)

27 (30.6%)

12 (15.3%)

37 (54.3%)

29 (38.6%)

67 (96.1%)

n=70

Abnormal Carotid Study

32 (27.4%)

20 (48.0%)

35 (21.6%)

24 (18.3%)

99 (63.5%)

64 (46.6%)

32 (23.8%)

17 (17.0%)

55 (37.9%)

101 (71.8%)

142 (96.1%)

n=148

Normal Carotid Study

Central Obesity defined as waist circumference ≥102 cm in males and ≥88 cm in females

Hypertension defined as blood pressure ≥130 mm Hg systolic and/or 85 mm Hg diastolic or the regular use of anti-hypertensive medication

8 (10.8%)

7 (51.1%)

30 (50.5%)

21 (28.1%)

39 (68.1%)

30 (55.5%)

30 (42.3%)

8 (13.6%)

40 (68.7%)

41 (68.6%)

60 (100.0%)

n=60

Abnormal Carotid Study

0.0406

0.8953

<0.0001

0.5305

0.0127

0.0005

0.0477

0.2123

0.0003

<0.0001

0.7837

p-value

Diabetes Mellitus defined based on 2010 American Diabetes Association definition (Hemoglobin A1C ≥6.5%, fasting plasma glucose ≥126 mg/dL, two-hour plasma glucose ≥200 mg/dL during 75 gram
oral glucose tolerance test, or random plasma glucose ≥200 mg/dL associated with classic symptoms of hyperglycemia or hyperglycemic crises)

4

3

2

High Sensitivity C-Reactive Protein ≥10 mg/L excluded

1

Data are adjusted for the probability of sampling using weights taking into consideration clustering effects arising from the same census block and household.

214 (52.4%)

Obesity

n=129
120 (94.2%)

n=407
389 (96.1%)
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Central Obesity2

Normal Carotid Study
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